International recognition of a Chinese drug to treat cancer – arabic.china.org.cn

International recognition of a Chinese medicine to treat cancer

BEIJING, Jan. 9 (Xinhua) – Chinese Centallamab, a drug used for the treatment of Hodgkin's lymphoma, has received international recognition and has published a clinical study on this drug in the January issue of The Lancet Hematology.

Hodgkin's lymphoma is rare and affects young people from 20 to 40 years old. Although the cure rate of the disease at the beginning of treatment, the proportion of the probability of return of the disease after healing for the first time, 20%. People with the disease do not have effective treatment in China.

The results showed that CintiLimab had a level of efficacy and appropriate toxicity in Chinese patients with the disease and that 80.4% of patients had a remarkable response.

The Chinese National Administration of Medical Products approved the property business license in December 2018.

<! – enpproperty 743584422019-01-10 11: 10: 08: 0Science of medicine in China10017189644Recent newsRecent newshttp://ar.china.org.cn/txt/2019-01/10/content_74358442.htmnoNancyXinhuaThe Chinese drug Synthalimb for the treatment of Hodgkin lymphoma has been recognized internationally and a clinical trial of the drug was published in the January issue of The Lancet Hematology.1/ enpproperty ->